The Catalyst Brief
Dr. Priya Nandakumar
Author

Dr. Priya Nandakumar

Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.

160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry

Page 10 of 14

FDA Reopens Safety Review of Mifepristone as Court Upholds Mail Access Amid Ongoing Regulatory ScrutinyRegulatory & Policy

FDA Reopens Safety Review of Mifepristone as Court Upholds Mail Access Amid Ongoing Regulatory Scrutiny

Following a recent court ruling on April 7, 2026, the FDA faces renewed pressure to finalize its internal safety assessment of mifepristone, a medication widely used for abortion services. The court’s decision preserves mail access for the drug, highlighting the complex regulatory and legal landscape influencing medication abortion availability in the U.S.

Dr. Priya NandakumarDr. Priya NandakumarApr 10, 2026
A New Health Care Blueprint From a Key Democratic Think Tank Targets AffordabilityRegulatory & Policy

A New Health Care Blueprint From a Key Democratic Think Tank Targets Affordability

As health care costs continue their upward trajectory, a prominent Democratic think tank has introduced an ambitious plan to tackle affordability. This blueprint aims to reshape health policy by addressing key cost drivers and proposing actionable reforms. The move signals a strategic push by Democrats to prioritize health care affordability ahead of forthcoming political contests, reflecting growing public demand for accessible and sustainable health services.

Dr. Priya NandakumarDr. Priya NandakumarApr 9, 2026
The Power Behind Enterprise EHR Software for Large Healthcare SystemsMedical Technology

The Power Behind Enterprise EHR Software for Large Healthcare Systems

Enterprise EHR software has become indispensable for large healthcare systems aiming to optimize clinical workflows and data management. This technological advancement fosters greater scalability and interoperability, improving patient care coordination and compliance with regulatory standards. As healthcare systems grow larger and more complex, adopting robust EHR systems is pivotal for sustainable governance and operational efficiency.

Dr. Priya NandakumarDr. Priya NandakumarApr 8, 2026
Amazon Partners with Berry Street to Enhance Access to Nutrition TherapyHealthcare Investment

Amazon Partners with Berry Street to Enhance Access to Nutrition Therapy

In a strategic move to facilitate better nutritional health, Amazon has teamed up with Berry Street to offer insurance-covered nutrition therapy services through its platform, aiming to increase accessibility and awareness among users. This development reflects the growing significance of nutrition therapy in healthcare.

Dr. Priya NandakumarDr. Priya NandakumarApr 3, 2026
6 FDA Decisions To Watch in Q2 2026Regulatory & Policy

6 FDA Decisions To Watch in Q2 2026

As we approach the second quarter of 2026, the Food and Drug Administration (FDA) has several high-profile decisions lined up that could significantly influence drug availability, market competition, and patient treatment options. These upcoming verdicts are particularly crucial in the areas of obesity management and other pressing health concerns.

Dr. Priya NandakumarDr. Priya NandakumarMar 30, 2026
Insilico Medicine and Lilly Forge $2.75 Billion AI-Driven Drug Commercialization AllianceAI in Drug Discovery

Insilico Medicine and Lilly Forge $2.75 Billion AI-Driven Drug Commercialization Alliance

The recent commercialization agreement between Lilly and AI drug developer Insilico Medicine represents the growing impact of AI technologies in pharmaceutical research and development. With $115 million upfront and potential biobucks totaling approximately $2.75 billion, this partnership underscores the transformative role AI now plays in drug discovery and commercialization processes.

Dr. Priya NandakumarDr. Priya NandakumarMar 29, 2026
FDA Grants Approval to Rocket Pharma's Gene Therapy Kresladi for Rare Immune DisorderRegulatory & Policy

FDA Grants Approval to Rocket Pharma's Gene Therapy Kresladi for Rare Immune Disorder

Rocket Pharma's Kresladi has secured FDA approval for the treatment of a rare immune disorder despite a limited clinical trial size. This approval underscores the ongoing evolution in gene therapy approaches and the regulatory acceptance of innovative treatments in rare disease spaces. The therapy's positive results in nine patients highlight the challenges and promises of addressing ultra-rare conditions.

Dr. Priya NandakumarDr. Priya NandakumarMar 27, 2026
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro AcquisitionBiopharmaceutical Industry

Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition

The $1.7 billion acquisition of Ouro Medicines by Gilead Sciences marks a significant advancement in the quest to address autoimmune conditions through immune system modulation. The collaboration with Galapagos heralds a potential new phase in drug development focused on resetting immune responses.

Dr. Priya NandakumarDr. Priya NandakumarMar 25, 2026
Inside One VC’s Litmus Test for Investable Healthcare AI StartupsAI in Drug Discovery

Inside One VC’s Litmus Test for Investable Healthcare AI Startups

Investing in healthcare AI requires a nuanced approach that addresses the complex dynamics of the industry. This article explores how venture capitalists make investment decisions with a focus on discerning the most promising healthcare AI companies.

Dr. Priya NandakumarDr. Priya NandakumarMar 21, 2026